Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000868278-26-000005
Filing Date
2026-06-01
Accepted
2026-06-01 17:13:49
Documents
104
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K prph-20251231.htm   iXBRL 10-K 1767011
2 EX-21.1 prph-20251231xexx211.htm EX-21.1 23230
3 EX-31.1 prph-20251231xexx311.htm EX-31.1 10818
4 EX-32.1 prph-20251231xexx321.htm EX-32.1 5282
10 prph-20251231_g1.gif GRAPHIC 2440
  Complete submission text file 0000868278-26-000005.txt   12391915

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prph-20251231.xsd EX-101.SCH 95507
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT prph-20251231_cal.xml EX-101.CAL 141016
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT prph-20251231_def.xml EX-101.DEF 508610
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prph-20251231_lab.xml EX-101.LAB 1151865
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prph-20251231_pre.xml EX-101.PRE 805622
108 EXTRACTED XBRL INSTANCE DOCUMENT prph-20251231_htm.xml XML 1632759
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-21617 | Film No.: 261052272
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)